A Clinical Case Study On HPV: Causes, Diagnosis, Treatment, Management and General Public Awareness

Abstract

Background: Human Orthopneumovirus (HOPV), formerly known as Respiratory Syncytial Virus (RSV), is a significant cause of lower respiratory tract infections, particularly in infants, the elderly, and immunocompromised individuals. Despite its global prevalence, HOPV often remains underdiagnosed and underestimated in clinical settings. Case Presentation: This case study presents a detailed clinical evaluation of a 6-month-old infant admitted with severe bronchiolitis and respiratory distress. Laboratory and radiological investigations confirmed HOPV infection. A comprehensive clinical approach including supportive therapy, oxygen supplementation, and close monitoring was employed. The patient responded positively to treatment and was discharged with complete recovery after 10 days. Discussion: The case underscores the importance of early diagnosis using rapid antigen detection tests and RT-PCR, especially during peak viral seasons. Although no specific antiviral treatment is currently approved, supportive care remains the cornerstone of management. Preventive strategies, including hand hygiene, avoidance of exposure, and recently approved monoclonal antibodies (e.g., nirsevimab), are essential in reducing disease burden. Conclusion: Heightened clinical awareness, timely diagnosis, and appropriate management of HOPV infections can significantly improve patient outcomes. Public health education and preventive strategies must be strengthened to reduce transmission, especially in high-risk groups.

Keywords

HPV, Disease, Causes General Public Awareness

Introduction

Human Papillomavirus (HPV) infection is one of the most common sexually transmitted infections (STIs) worldwide, posing a significant public health concern. HPV refers to a group of more than 200 related viruses, out of which more than 40 are known to be transmitted through sexual contact. These viruses infect the skin and mucous membranes of humans, affecting areas such as the genital tract, anus, mouth, and throat. While most HPV infections are harmless and resolve on their own, certain high-risk types can lead to serious health complications, including various forms of cancer, especially cervical cancer.(1) The increasing prevalence of HPV, coupled with its strong association with cervical and other genital cancers, has attracted global medical attention. According to the World Health Organization (WHO), nearly all sexually active men and women will contract HPV at some point in their lives. However, the majority remain unaware of their infection due to its asymptomatic nature. This lack of symptoms and the general unawareness surrounding the infection contribute significantly to the continued spread of the virus, leading to serious health implications. HPV is generally categorized into two major types: low-risk HPV types, which can cause skin warts and genital warts, and high-risk HPV types, which have the potential to cause cancers. The most well-known high-risk types are HPV 16 and HPV 18, which together cause approximately 70% of cervical cancer cases. Other high-risk types such as HPV 31, 33, 45, 52, and 58 also contribute to cancer development. On the other hand, HPV 6 and 11 are the most common low-risk types, responsible for over 90% of genital wart cases. One of the primary concerns with HPV infection is its silent progression. The virus can remain dormant in the body for years without any visible symptoms. In many individuals, the immune system successfully clears the virus within one to two years. However, in some cases where the infection persists, especially with high-risk types, it can lead to precancerous changes in the tissues. If left undetected and untreated, these changes may eventually develop into cancer over time. This is especially true for cervical cancer, which typically progresses slowly, making it a potentially preventable disease through timely screening and intervention. In countries like India, cervical cancer is one of the leading causes of cancer-related deaths among women. Every year, thousands of women are diagnosed with cervical cancer, and a large proportion of them lose their lives to this disease. What is more alarming is that most of these cases could have been prevented through routine screening and HPV vaccination. The low awareness levels, limited access to healthcare facilities, social stigma around sexual health, and lack of proper education are some of the key barriers in the prevention of HPV-related diseases. (2) Despite the availability of preventive measures like HPV vaccines, which have been proven safe and effective, vaccination rates remain low in many parts of the world, including India. The vaccines such as Gardasil and Cervarix provide protection against the most common cancer-causing HPV types. These vaccines are most effective when administered before individuals become sexually active, generally recommended for girls and boys between the ages of 9 and 14. In several developed countries, national immunization programs have helped reduce the incidence of HPV-related diseases significantly, yet many developing nations still lag behind in implementing such initiatives. (3) Another critical aspect in preventing the adverse effects of HPV is screening, especially among women. The Pap smear test and HPV DNA test are essential tools for early detection of cervical abnormalities. Regular screening helps in identifying precancerous lesions before they progress to invasive cancer. However, in many low-resource settings, women are either unaware of the importance of these tests or lack access to such services, resulting in delayed diagnosis and treatment. This clinical case study focuses on understanding the real-life implications of HPV infection by analyzing an actual patient case. Through the lens of this case, the study aims to explore the biological, medical, psychological, and social dimensions of HPV. It also evaluates the effectiveness of current prevention and treatment methods, and emphasizes the role of public health education in managing HPV-related disease burden. Public awareness plays a pivotal role in the prevention and control of HPV. Unfortunately, many individuals still associate HPV and other STIs with moral or social taboos, making it difficult to have open conversations about sexual health. This stigma leads to poor health-seeking behavior, especially among women. Promoting sexual health education in schools, colleges, and communities can help normalize these discussions and empower individuals to take control of their reproductive health.(4) Government intervention is another crucial element. In India, recent steps have been taken to include HPV vaccination in national immunization programs in certain states. However, widespread implementation and sustained efforts are needed to make these vaccines accessible and acceptable across the country. Public-private partnerships, awareness campaigns, and healthcare training are essential in achieving long-term goals. Globally, WHO has launched an initiative to eliminate cervical cancer as a public health problem. The strategy includes the "90-70-90 targets(5) 90% of girls fully vaccinated with HPV vaccine by the age of 15,70% of women screened with a high-performance test by 35 years and again by 45 years,90% of women identified with cervical disease receiving appropriate treatment.This integrated strategy highlights the importance of combining vaccination, screening, and treatment to control HPV-related health issues. It also underlines the need for countries like India to strengthen their healthcare infrastructure and policy-making in this direction.In conclusion, HPV is not just a medical issue—it is a social, psychological, and educational concern. This infection, although common, can lead to severe outcomes like cancer if not addressed in time. With proper vaccination, early screening, and enhanced public awareness, the burden of HPV-related diseases can be drastically reduced. This project aims to shine a light on the comprehensive aspects of HPV infection through a clinical case study, with a broader goal of contributing to ongoing efforts in public health promotion and disease prevention.(6)

Types of HPV Disease.

Human Papillomavirus (HPV) is a group of more than 200 related viruses, and they are categorized based on the type of disease they cause. Broadly, HPV diseases are classified into two types: low-risk and high-risk. Low-risk HPV types mainly cause benign (non-cancerous) conditions. The most common low-risk types are HPV-6 and HPV-11. These types are associated with conditions like genital warts and respiratory papillomatosis (a rare condition where warts grow in the air passages leading from the nose and mouth into the lungs). Although uncomfortable, these conditions are not life-threatening and do not cause cancer. On the other hand, high-risk HPV types are oncogenic (cancer-causing). Persistent infection with high-risk HPV can lead to the development of several types of cancers over time. The most dangerous types are HPV-16 and HPV-18, which are responsible for the majority of HPV-related cancers. High-risk HPV infections can cause:

Cervical cancer (most commonly) Anal cancer

Oropharyngeal cancer (cancer in the back of the throat, including the base of the tongue and tonsils) Penile cancer (in men) Vulvar and vaginal cancers (in women) It is important to understand that not everyone infected with HPV develops cancer. In most cases, the immune system clears the virus naturally within two years. However, if the infection persists, it can cause abnormal cell changes that may progress to cancer over time. Vaccination against HPV, regular screening (such as Pap smears), and safe sexual practices can significantly reduce the risk of HPV infections and related diseases. Thus, HPV diseases range from minor skin warts to serious cancers, depending on the HPV type involved. (7)

5. Aim And Objective

Aim:

To study the A clinical case study of HPV disease causes, symptoms, diagnosis, treatment, and public awareness regarding Human Papillomavirus (HPV) infection, and to emphasize the importance of early screening and vaccination in preventing HPV-related complications.

Objectives:

1. To understand the etiology and risk factors associated with HPV infection.
2. To study the common clinical symptoms and types of HPV.
3. To explore the current diagnostic methods used for early detection of HPV
4. To review available treatment options for HPV-related conditions.
5. To assess the level of public awareness and perception about HPV infection and vaccination.
6. To highlight the importance of preventive measures, especially vaccination and regular screening.
7. To analyze a clinical case of HPV infection for a better understanding of real-world presentation and management

5. Etiology

Introduction to Etiology:

Etiology refers to the study of the causes or origins of a disease. In the case of HPV (Human Papillomavirus), the etiology involves understanding how the virus is transmitted, what factors contribute to infection, and the biological nature of the virus that enables it to persist and cause disease. (13)

1. Causative Agent:

HPV is caused by Human Papillomavirus, a small, non-enveloped DNA virus belonging to the Papilloma viridae family. Over 200 genotypes of HPV have been identified, of which more than 40 infect the anogenital region. Low-risk HPV types: e.g., HPV 6 and 11 – cause genital warts, low-grade cervical changes. High-risk HPV types: e.g., HPV 16, 18, 31, 33 – associated with cervical, anal, penile, vulvar, and oropharyngeal cancers (14,15)

2. Mode of Transmission:

• HPV is primarily transmitted through skin-to-skin contact, especially during:
• Sexual activity: vaginal, anal, or oral sex.
• Genital contact without penetration.
• Vertical transmission: from mother to child during childbirth (rare).
• The virus enters the body through microscopic abrasions or cuts in the skin or mucosa.

3. Risk Factors for Infection:

Several risk factors increase the likelihood of acquiring and persisting with HPV infection:

Early onset of sexual activity Multiple sexual partners Unprotected sex Weakened immune system (e.g., HIV-positive individuals) Smoking and tobacco use Poor genital hygiene Lack of vaccination Other STIs (Sexually Transmitted Infections) (16)

4. Pathophysiology of HPV:

Once HPV enters the body, it infects the basal epithelial cells of the skin or mucous membranes. The virus uses host cell machinery to replicate its DNA and produce viral proteins. In most cases, the immune system clears the infection within 1–2 years. In high-risk HPV infections, the virus may integrate its DNA into the host genome, leading to disruption of tumor suppressor genes (p53 and Rb), which results in uncontrolled cell growth and cancer.(17)

5. Incubation Period:

The incubation period for HPV varies from weeks to several months. Because the infection is often asymptomatic, it may remain unnoticed for years.

6. Types of HPV-related Conditions: Benign Conditions: Genital warts

Respiratory papillomatosis (rare)Malignant Conditions (High-risk HPV): Cervical cancer  Anal cancer Penile cancer Vaginal and vulvar cancer Oropharyngeal cancer (18,19)

5. Diagnosis

Diagnosing HPV infection is crucial because most HPV infections are asymptomatic, meaning individuals may carry and transmit the virus without knowing it. Early and accurate diagnosis helps in preventing cervical cancer and other HPV-related complications, especially when caused by high-risk HPV types. Diagnosis involves screening tests, laboratory investigations, and visual examination, depending on the patient’s symptoms, age, and risk profile.(20)

1. Clinical Examination:

Visual inspection of genital warts or lesions during physical or gynecological examination is often the first step. In women, the cervix is visually inspected using a speculum to check for abnormal lesions. In men, visible genital warts may indicate HPV infection, but often no visible signs are present.(21)

2. Pap Smear Test (Papanicolaou Test):

This is the primary screening test for cervical cancer.

It detects abnormal changes in cervical cells that may be caused by HPV. Recommended every 3 years for women aged 21–65 years, or as advised by a doctor  .A positive Pap smear doesn’t confirm HPV, but suggests the need for further testing.

3. HPV DNA Test:

This test detects the presence of high-risk HPV DNA in cervical cells.Often done alongside the Pap smear or if Pap results are abnormal. Can identify the exact HPV type (e.g., HPV 16, 18).Recommended for:Women aged 30 years and above Women with abnormal Pap smear results(22)

4. VIA (Visual Inspection with Acetic Acid):

A low-cost screening method used in low-resource settings. The cervix is swabbed with 3–5% acetic acid (vinegar), and areas that turn white are considered abnormal. Useful in community health screening where advanced tests are not available.

5. Colposcopy:

A follow-up diagnostic procedure done if Pap smear or VIA results are abnormal. A colposcope (a special microscope) is used to examine the cervix under magnification. Doctors may perform a biopsy during colposcopy to test a small tissue sample for precancer or cancer. (23)

6. Biopsy:

Used to confirm cervical cancer or precancerous lesions. Performed during colposcopy, or in case of persistent genital warts or abnormal tissue growths. The sample is sent to a lab for histopathological examination.

7. Anal and Oral HPV Screening:

Performed in high-risk populations (e.g., men who have sex with men, HIV-positive individuals). Involves swabbing the anal canal or oral cavity to detect HPV DNA. Not part of routine screening for the general population.

8. HPV Testing in Men:

Currently, no routine HPV test is recommended for men, except in research or high-risk situations. Diagnosis is generally based on visual identification of warts or biopsy if cancer is suspected.

9. Self-Sampling Methods:

In some countries, self-collected cervical or vaginal swabs for HPV DNA testing are being used. Helpful in increasing screening coverage, especially in rural or socially conservative populations.

10. Role of Laboratory Tests:

Advanced tests like PCR (Polymerase Chain Reaction) and Hybrid Capture 2 are used in labs to detect and quantify HPV DNA. These help in: Confirming diagnosis Typing HPV strains Monitoring treatment outcomes (23)

5. Treatment

There is currently no cure for the HPV virus itself, but many of its effects and complications are treatable. In most healthy individuals, the immune system clears the virus naturally within 1–2 years. However, when the infection persists—especially with high-risk HPV types—it can lead to precancerous changes or cancer, requiring medical intervention. Treatment strategies focus on managing the symptoms, removing abnormal tissue, and preventing complications such as cervical cancer.(24)

1. Natural Clearance of HPV:

In 80–90% of cases, the immune system clears HPV on its own within 1 to 2 years. No treatment is required if the infection is asymptomatic and the immune system is healthy. Regular monitoring and follow-up are recommended in case of persistent infection.

2. Treatment of Genital Warts (Low-risk HPV):

Genital warts, usually caused by HPV types 6 and 11, are non-cancerous but can cause discomfort and emotional distress.

2. 1. Topical Treatments: Imiquimod cream – boosts immune response. Podophyllin or podofilox – destroys wart tissue. Trichloroacetic acid (TCA) – chemical cauterization.
   2. Cryotherapy: Freezing the wart using liquid nitrogen. Effective and commonly used; may require multiple sessions.
   3. Electrocautery: Burning off the wart using electric current. Usually done under local anesthesia.
   4. Laser Therapy:  Used for larger or hard-to-treat warts.  Expensive and usually reserved for resistant cases.
   5. Surgical Removal: Simple excision of the wart. Effective for bulky or recurrent lesions.(25)
3. Treatment of Precancerous Cervical Lesions (High-risk HPV):

If screening tests detect abnormal cells on the cervix, treatment is required to prevent progression to cancer.

3. 1. Cryotherapy: Freezing abnormal cells.
   2. LEEP (Loop Electrosurgical Excision Procedure):Uses an electrical wire loop to cut away abnormal tissue. Often used for CIN 2 and CIN 3 (moderate to severe dysplasia).
   3. Cone Biopsy (Conization): Surgical removal of a cone-shaped section of the cervix. Used when deeper tissue involvement is suspected.
   4. Follow-up Pap Smears & HPV DNA Test Done every 6–12 months post-treatment to monitor recurrence.(26)
4. Treatment of HPV-related Cancers: If HPV leads to cancer (like cervical, anal, throat, or penile cancer), standard oncological treatments are used:
   1. Surgery: Removal of cancerous tissue or organ (e.g., hysterectomy for cervical cancer)
   2. Radiation Therapy: High-energy rays to kill cancer cells
   3. Chemotherapy: Anti-cancer drugs used in combination with radiation or surgery
   4. Targeted Therapy / Immunotherapy: In advanced or recurrent cases, newer treatments may be used to boost the body’s immune response to cancer.(27)
5. HPV Vaccination (Prevention is Best Treatment):

HPV vaccines (Gardasil, Cervarix, Gardasil 9) are effective in preventing infection, especially if taken before sexual debut. Vaccination is recommended for: Girls and boys aged 9–14 years.  individuals up to 26 years (and in some cases up to 45 years) if not previously vaccinated.(28)

6. Lifestyle and Supportive Measures:

Boosting immunity through healthy diet, regular exercise, and avoiding smoking. Counseling and psychological support for patients dealing with HPV-related stigma or emotional stress. Partner testing and safe sex practices to prevent reinfection and transmission. (29

5. Prevention

• Vaccination:

• Take HPV vaccination (Gardasil or Cervarix) at the recommended age (9–26 years ideally, before sexual activity begins).
• Complete the full vaccination schedule (2 or 3 doses depending on age).
• Promote male vaccination as it helps reduce transmission and protects against penile, anal, and oropharyngeal cancers.
• Encourage catch-up vaccination in individuals up to age 45 if unvaccinated.
• Educate parents and guardians about the safety and importance of HPV vaccines for children. (29)

• Safe Sexual Practices:

• Use condoms consistently and correctly to reduce HPV transmission risk (not 100% protection).
• Limit the number of sexual partners to reduce exposure.
• Avoid early onset of sexual activity, which is associated with increased risk.
• Ensure mutual monogamy with a tested and uninfected partner.
• Avoid sexual contact with individuals showing visible genital warts or known HPV infection.(30)

• Regular Screening and Medical Checks:

• Undergo regular Pap smears for women (starting from age 21 or as advised).
• Use HPV DNA testing for more accurate detection of high-risk types.
• Follow up on abnormal Pap test results promptly.
• Attend gynecological check-ups regularly for early signs of infection or complications.
• Encourage screening even after vaccination, as vaccines don’t cover all HPV types.(31)

• Health and Hygiene Awareness:
• Avoid sharing personal items like towels or undergarments.
• Maintain genital hygiene to prevent infections.
•  Avoid smoking, as it weakens immune response and increases HPV persistence.
•  Boost immunity with a healthy lifestyle (balanced diet, sleep, exercise).
• Educate the public and students about HPV through awareness campaigns, especially in   schools and colleges. (32)

5. METHODOLOGY

This clinical case study was conducted using a descriptive and observational approach to understand various aspects of Human Papillomavirus (HPV) infection. The methodology involved the following steps:

1. Case study

A clinically confirmed case of HPV infection was selected from a hospital/clinical setting with proper patient consent and ethical considerations. (33)

2. Data Collection:

Detailed patient history, including age, gender, sexual history, presenting symptoms, and previous medical records, was collected. Clinical findings were recorded through physical examination and diagnostic test reports (e.g., Pap smear, HPV DNA testing).

3. Diagnostic Assessment:

Lab reports and imaging studies were analyzed to confirm the diagnosis. The HPV strain type (high-risk or low-risk) was identified based on molecular test results. (34)

4. Treatment Plan Review:

Treatment provided to the patient was documented, including medical, surgical, or supportive therapies. Patient response to treatment was monitored during follow-up visits.

5. Public Awareness Evaluation:

A brief survey or informal interview was conducted among a small group of individuals (students/patients/general public) to assess knowledge, awareness, and attitude toward HPV and its vaccine.

6. Literature Review:

Relevant literature from research articles, WHO/CDC reports, and clinical guidelines was reviewed to support the understanding of HPV infection, its complications, and prevention strategies. (35)

7. Data Analysis and Interpretation:

Collected data was analyzed qualitatively and presented in the form of charts, tables, or descriptive summaries. Observations were compared with established literature to draw valid conclusions. (36)

5. Case Study

1. Patient Profile:

Name: Mr. Amol lunge

Age: 28 years

Sex: Male

Marital Status: unmarried

Occupation: education

Residence: Semi-urban area

2. Chief Complaint:

Blood-tinged urine (hematuria), mild lower abdominal pain

3. History of Present Illness:

The patient reported episodes of blood in the urine intermittently for the past 4 months, along with mild lower abdominal discomfort. He also experienced occasional burning sensation while urinating but no fever, weight loss, or abnormal penile discharge (37)

4. Past Medical History: No known chronic illness

No prior surgeries

Not vaccinated for HPV

No family history of cancer

5. Personal and Sexual History:

Married at the age of 24

Monogamous relationship

No known sexually transmitted infections in the past. Wife has no known gynecological complaints

6. Clinical Examination:

General Condition: Stable

Vitals: Within normal limits

External genitalia exam: No visible lesions

Digital rectal exam: Mild tenderness near the prostate area

Inguinal region: No lymphadenopathy (38)

7. Investigations:

Urine Cytology: Atypical squamous cells identified

HPV DNA Test (Penile swab): Positive for high-risk HPV type 16

Penile Colposcopy: Acetowhite lesions observed, suspicious for penile intraepithelial neoplasia (PeIN 2)

Biopsy of Lesion: Histopathology confirmed Penile Intraepithelial Neoplasia Grade 2 (PeIN 2) (39)

8. Diagnosis:

High-Risk HPV Infection (Type 16) leading to Penile Intraepithelial Neoplasia (PeIN 2)

9. Treatment Given:

Excisional therapy (Laser ablation) was done to remove the affected tissue.

Patient was advised follow-up every 6 months for 1 year with repeat HPV testing and cytology.

Counseling was done regarding HPV transmission, use of condoms, and HPV vaccination for his children (aged 12 and 14).

Lifestyle advice included avoiding tobacco (chewing form), maintaining genital hygiene, and safe sexual practices. (40)

10. Prognosis:

At 6 months follow-up, repeat HPV DNA test was negative, and cytology was normal. The patient remains asymptomatic and is under routine yearly surveillance.

Public Health Note:

This case highlights the importance of:Awareness and screening in males, especially those with symptoms like blood-tinged urine or genital lesions, HPV DNA testing for early detection of high-risk strains

HPV vaccination for both genders before sexual debut

Regular sexual health check-ups and counseling about STI prevention (41)

5. Public Awareness

Public Awareness on Human Papillomavirus (HPV)

Introduction:

Human Papillomavirus (HPV) is one of the most common sexually transmitted infections (STIs) worldwide. While most HPV infections go unnoticed and resolve on their own, some types—especially high-risk HPV types like 16 and 18—can lead to serious health complications, including cervical cancer, anal cancer, throat cancer, and genital warts. Therefore, public awareness and education about HPV are crucial to prevent its spread and associated diseases. (42)

Why Public Awareness is Important:

1. Early Detection and Prevention:

Educating people about the signs, symptoms, and modes of transmission of HPV encourages early screening and timely treatment. Awareness can reduce the risk of progression to cancer by promoting routine Pap smears and HPV testing.

2. Reducing Stigma:

Since HPV is sexually transmitted, many people avoid talking about it due to social taboos. Public awareness campaigns can normalize conversations about sexual health and encourage people to seek medical help without shame

3. Promotion of HPV Vaccination: The HPV vaccine is highly effective in preventing infection from high-risk HPV types. Educating parents and adolescents about timely vaccination (usually between ages 9–14) can significantly reduce future cancer risks.
4. Safer Sexual Practices: Promoting safe sex practices like the use of condoms, limiting the number of sexual partners, and regular check-ups can minimize HPV transmission
5. Community Involvement: Involving schools, colleges, healthcare centers, NGOs, and media platforms in awareness campaigns ensures that accurate information reaches a larger audience.

HPV can affect both men and women. Most HPV infections are silent (no symptoms) but can still spread to others. HPV is the leading cause of cervical cancer, but it is preventable. Regular Pap smears and HPV tests help detect changes early HPV vaccination is safe, effective, and life-saving. Safe sex and open communication with healthcare providers are important. (43,44)

Methods of Creating Public Awareness:

1.  Health Education Programs:

Organized in schools, colleges, and community centers focusing on adolescent health.

2. Media Campaigns:

Use of TV, radio, social media, and newspapers to share facts about HPV and prevention.

3.  Healthcare Professional Counseling:

Doctors, nurses, and pharmacists can counsel patients during visits about HPV, screening, and vaccination.

4. Posters and Pamphlets:

Distributing easy-to-understand materials in local languages with visuals to spread awareness.

5. Government and NGO Initiatives:

Government-led free vaccination drives, and NGO support in rural and semi-urban areas where awareness is limited. (45)

Essential Information to Give to the Public About HPV

1. How is HPV Spread?

Through vaginal, anal, or oral sex with an infected person. Can also spread by skin-to-skin contact in the genital area. A person can have HPV even if they have no symptoms.

2. What Are the Symptoms?

Most HPV infections do not show any symptoms. Some people may develop:genital warts Abnormal vaginal bleeding Pelvic pain (in later stages of cervical changes)

3. What Are the Risks ?  Some HPV types can cause Cervical cancer (in women)Anal, throat, vulvar, vaginal, and penile cancers Long-term infection with high-risk HPV increases cancer risk.
4. How Can It Be Prevented?

HPV Vaccine Safe and effective Recommended for girls and boys aged 9–14 years Can also be given up to age 26 (and sometimes beyond).

Safe Sexual Practices: Use condoms properly and consistently. Limit the number of sexual partners Regular sexual health check-ups.

5. Why Is Screening Important?

Women should get Pap smear tests starting from age 21 (or as advised). HPV testing detects high-risk virus types before cancer develops. Early detection = early treatment = cancer prevention.

6. What Should the Public Do?

• Get children vaccinated at the recommended age.
• Go for regular checkups (especially women).
• Spread awareness in families, schools, and local communities.
• Break the silence about sexual health—it’s part of overall health(46

5. Summary

This clinical case study focuses on Human Papillomavirus (HPV), one of the most common sexually transmitted infections (STIs) worldwide. The report covers various essential aspects such as its causes, symptoms, diagnosis, treatment, a real-life case study, and public awareness strategies. HPV is a viral infection transmitted primarily through sexual contact. While many types of HPV are harmless and go away on their own, some high-risk types can lead to serious conditions such as cervical cancer, anal cancer, and genital warts. The infection is most common among sexually active individuals, especially adolescents and young adults. HPV is caused by a group of more than 100 related viruses, with over 40 of them transmitted through sexual contact. It spreads through vaginal, anal, or oral sex, and even skin-to-skin contact in the genital area. Factors like early sexual activity, multiple partners, weakened immunity, and lack of vaccination increase the risk of infection. HV infection is often asymptomatic, meaning most people do not realize they are infected. Some visible symptoms include:

Genital warts

Respiratory papillomatosis (rare)

In some cases, persistent infection with high-risk HPV types can lead to precancerous lesions and cancers. HPV is diagnosed through: Pap smear test – detects abnormal cervical cells. HPV DNA test – identifies high-risk virus types. Visual inspection – for genital warts or lesions. There is no cure for the virus itself, but Warts can be removed through topical treatments or procedures. Precancerous lesions may be treated with surgery or cryotherapy

Regular follow-ups are essential for high-risk patients.

The report includes a real-world case of a young woman diagnosed with high-risk HPV during a routine Pap smear. She underwent further evaluation, received treatment for precancerous cervical changes, and was educated about lifestyle modifications and follow-up care. Public awareness is a crucial part of HPV prevention and includes: Educating people about HPV transmission and risks Promoting safe sex practice Encouraging HPV vaccination in boys and girls aged 9–14 Reducing the stigma associated with sexual health Regular screening and early detection. Awareness can be spread through: Hospitals, schools, and NGOs Mass media, social media, and community outreach Government programs like National Health Mission Posters, leaflets, and health education campaign

5. CONCLUSION

Human Papillomavirus (HPV) is a highly prevalent viral infection that affects millions of people worldwide, often without their knowledge. Although many HPV infections are harmless and resolve on their own, certain high-risk types are strongly linked to serious health conditions such as cervical cancer, anal cancer, and other genital and oropharyngeal cancers. Through this case study and research, it is evident that awareness, early detection, vaccination, and timely treatment are the most effective tools in combating the complications associated with HPV. The introduction of the HPV vaccine, regular screening programs like the Pap smear, and widespread health education campaigns have significantly improved the prevention and control of HPV-related diseases. However, social stigma, lack of knowledge, and limited access to healthcare, especially in rural areas, remain major barriers.

Therefore, it is essential to focus on public awareness, youth education, and strengthening healthcare services to ensure that individuals are informed and protected. With combined efforts from the healthcare system, educational institutions, governments, and communities, the burden of HPV-related diseases can be drastically reduced. This project emphasizes that prevention is better than cure, and by empowering people with the right information and resources, we can work towards a healthier and cancer-free future

REFERENCES

1. World Health Organization. (2023). Human Papillomavirus (HPV) and Cervical Cancer. Retrieved from https://www.who.int/
2. Centers for Disease Control and Prevention. (2022). HPV Vaccination. https://www.cdc.gov/
3. Schiffman, M., Castle, P.E. (2005). The promise of global cervical-cancer prevention. New England Journal of Medicine, 353(20), 2101-2104.
4. Park, K. (2021). Preventive and Social Medicine. BanarsidasBhanot Publishers.
5. Bosch, F. X., & de Sanjosé, S. (2003). Human papillomavirus and cervical cancer—burden and assessment of causality. Journal of the National Cancer Institute Monographs, (31), 3-13.
6. Munoz, N., Bosch, F. X., de Sanjose, S., et al. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine, 348(6), 518-527.
7. Centers for Disease Control and Prevention (CDC). (2022). Human Papillomavirus (HPV) and Related Diseases. Retrieved from https://www.cdc.gov/hpv/parents/about-hpv.html
8. National Cancer Institute. (2022). HPV and Cancer. Retrieved from https://www.cancer.gov/
9. Doorbar, J. (2006). Molecular biology of human papillomavirus infection and cervical cancer. Clinical Science, 110(5), 525-541.
10. Villa, L. L. (2006). Prophylactic HPV vaccines: reducing the burden of HPV-related diseases. Vaccine, 24(Supplement 3), S23-S28.
11. Joura, E. A., Giuliano, A. R., Iversen, O. E., et al. (2015). A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New England Journal of Medicine, 372(8), 711-723.
12. World Health Organization. (2023). Human Papillomavirus (HPV) and Cervical Cancer. Retrieved from https://www.who.int/
13. Centers for Disease Control and Prevention. (2022). HPV Vaccination. https://www.cdc.gov/
14. Schiffman, M., Castle, P.E. (2005). The promise of global cervical-cancer prevention. New England Journal of Medicine, 353(20), 2101-2104.
15. Park, K. (2021). Preventive and Social Medicine. BanarsidasBhanot Publishers.
16. Bosch, F. X., & de Sanjosé, S. (2003). Human papillomavirus and cervical cancer—burden and assessment of causality. Journal of the National Cancer Institute Monographs, (31), 3-13.
17. Munoz, N., Bosch, F. X., de Sanjose, S., et al. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine, 348(6), 518-527.
18. National Cancer Institute. (2022). HPV and Cancer. Retrieved from https://www.cancer.gov/
19. Doorbar, J. (2006). Molecular biology of human papillomavirus infection and cervical cancer. Clinical Science, 110(5), 525-541.
20. Villa, L. L. (2006). Prophylactic HPV vaccines: reducing the burden of HPV-related diseases. Vaccine, 24(Supplement 3), S23-S28.
21. Joura, E. A., Giuliano, A. R., Iversen, O. E., et al. (2015). A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New England Journal of Medicine, 372(8), 711-723.
22. World Health Organization. (2023). Human Papillomavirus (HPV) and Cervical Cancer. Retrieved from https://www.who.int/
23. Centers for Disease Control and Prevention. (2022). HPV Vaccination. https://www.cdc.gov/
24. Schiffman, M., Castle, P.E. (2005). The promise of global cervical-cancer prevention. New England Journal of Medicine, 353(20), 2101-2104.
25. Park, K. (2021). Preventive and Social Medicine. BanarsidasBhanot Publishers.
26. Bosch, F. X., & de Sanjosé, S. (2003). Human papillomavirus and cervical cancer—burden and assessment of causality. Journal of the National Cancer Institute Monographs, (31), 3-13.
27. Munoz, N., Bosch, F. X., de Sanjose, S., et al. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine, 348(6), 518-527.
28. National Cancer Institute. (2022). HPV and Cancer. Retrieved from https://www.cancer.gov/
29. Doorbar, J. (2006). Molecular biology of human papillomavirus infection and cervical cancer. Clinical Science, 110(5), 525-541.
30. Villa, L. L. (2006). Prophylactic HPV vaccines: reducing the burden of HPV-related diseases. Vaccine, 24(Supplement 3), S23-S28.
31. Joura, E. A., Giuliano, A. R., Iversen, O. E., et al. (2015). A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New England Journal of Medicine, 372(8), 711-723.
32. World Health Organization. (2023). Human Papillomavirus (HPV) and Cervical Cancer. Retrieved from https://www.who.int/
33. Centers for Disease Control and Prevention. (2022). HPV Vaccination. https://www.cdc.gov/
34. Schiffman, M., Castle, P.E. (2005). The promise of global cervical-cancer prevention. New England Journal of Medicine, 353(20), 2101-2104.
35. Park, K. (2021). Preventive and Social Medicine. BanarsidasBhanot Publishers.
36. Bosch, F. X., & de Sanjosé, S. (2003). Human papillomavirus and cervical cancer—burden and assessment of causality. Journal of the National Cancer Institute Monographs, (31), 3-13.
37. Munoz, N., Bosch, F. X., de Sanjose, S., et al. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine, 348(6), 518-527.
38. National Cancer Institute. (2022). HPV and Cancer. Retrieved from https://www.cancer.gov/
39. Doorbar, J. (2006). Molecular biology of human papillomavirus infection and cervical cancer. Clinical Science, 110(5), 525-541.
40. Villa, L. L. (2006). Prophylactic HPV vaccines: reducing the burden of HPV-related diseases. Vaccine, 24(Supplement 3), S23-S28.
41. Joura, E. A., Giuliano, A. R., Iversen, O. E., et al. (2015). A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New England Journal of Medicine, 372(8), 711-723.
42. World Health Organization. (2023). Human Papillomavirus (HPV) and Cervical Cancer. Retrieved from https://www.who.int/
43. Centers for Disease Control and Prevention. (2022). HPV Vaccination. https://www.cdc.gov/
44. Schiffman, M., Castle, P.E. (2005). The promise of global cervical-cancer prevention. New England Journal of Medicine, 353(20), 2101-2104.
45. Park, K. (2021). Preventive and Social Medicine. BanarsidasBhanot Publishers.
46. Bosch, F. X., & de Sanjosé, S. (2003). Human papillomavirus and cervical cancer—burden and assessment of causality. Journal of the National Cancer Institute Monographs, (31).